|
|
|
|
| LEADER |
01000cam a2200265 4500 |
| 001 |
719606985 |
| 003 |
DE-627 |
| 005 |
20230905072126.0 |
| 007 |
tu |
| 008 |
120717s2013 xxk||||| 00| ||eng c |
| 010 |
|
|
|a 2012027538
|
| 020 |
|
|
|a 9780470976364
|c paper
|9 978-0-470-97636-4
|
| 020 |
|
|
|a 9780470976357
|c cloth
|9 978-0-470-97635-7
|
| 035 |
|
|
|a (DE-627)719606985
|
| 035 |
|
|
|a (DE-599)GBV719606985
|
| 035 |
|
|
|a (OCoLC)934736828
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 044 |
|
|
|c XA-GB
|
| 050 |
|
0 |
|a RS200
|
| 060 |
|
0 |
|a QV 779
|
| 082 |
0 |
|
|a 615.1/9
|q LOC
|2 23
|
| 084 |
|
|
|a 15,3
|2 ssgn
|
| 084 |
|
|
|a VX 5200
|q BVB
|2 rvk
|0 (DE-625)rvk/147798:253
|
| 084 |
|
|
|a 58.28
|2 bkl
|
| 100 |
1 |
|
|a Gaisford, Simon
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Essentials of pharmaceutical preformulation
|c Simon Gaisford; Mark Saunders
|
| 263 |
|
|
|a 1212
|
| 264 |
|
1 |
|a Chichester, West Sussex
|b John Wiley & Sons
|c 2013
|
| 300 |
|
|
|a XI, 252 S.
|b Ill., graph. Darst.
|c cm
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Includes bibliographical references and index
|
| 505 |
8 |
0 |
|a Basic principles of preformulation studies -- Ionisation constants -- Partitioning affinity -- Solubility -- Dissolution -- Salt selection -- Physical form I : crystalline materials -- Physical form II : amorphous materials -- Stability assessment -- Particle properties -- Powder properties.
|
| 650 |
|
2 |
|a Drug Compounding
|x methods
|
| 650 |
|
2 |
|a Drug Discovery
|x methods
|
| 650 |
|
4 |
|a Drugs / Design / Methodology
|
| 689 |
0 |
0 |
|D s
|0 (DE-588)4045699-7
|0 (DE-627)104162406
|0 (DE-576)209066407
|a Pharmazeutische Technologie
|2 gnd
|
| 689 |
0 |
1 |
|D s
|0 (DE-588)4068874-4
|0 (DE-627)104798866
|0 (DE-576)209174951
|a Arzneiform
|2 gnd
|
| 689 |
0 |
2 |
|D s
|0 (DE-588)4246877-2
|0 (DE-627)104809191
|0 (DE-576)210483121
|a Formulierung
|g Technische Chemie
|2 gnd
|
| 689 |
0 |
|
|5 (DE-627)
|
| 700 |
1 |
|
|a Saunders, Mark
|d 1976 Sept. 18-
|4 oth
|
| 856 |
4 |
2 |
|u http://www.gbv.de/dms/bs/toc/719606985.pdf
|m V:DE-601
|m B:DE-84
|q pdf/application
|v 2013-06-20
|x Verlag
|y Inhaltsverzeichnis
|3 Inhaltsverzeichnis
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a ISIL_DE-84
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OPC-PHA
|
| 912 |
|
|
|a SSG-OPC-DE-84
|
| 936 |
r |
v |
|a VX 5200
|b Allgemeines
|k Chemie und Pharmazie
|k Pharmazeutische Technologie einschl. Biopharmazie
|k Pharmazeutische Technologie allgemein
|k Physikalisch-chemische (theoretische) Grundlagen der Pharmazeutischen Technologie
|k Allgemeines
|0 (DE-627)1271941864
|0 (DE-625)rvk/147798:253
|0 (DE-576)201941864
|
| 936 |
b |
k |
|a 58.28
|j Pharmazeutische Technologie
|0 (DE-627)106417622
|
| 951 |
|
|
|a BO
|
| 953 |
|
|
|2 045F
|a 615.1/9
|
| 980 |
|
|
|2 20
|1 01
|x 0084
|b 1382469039
|c 00
|f --%%--
|d 2927-5052
|e --%%--
|j --%%--
|y k
|z 14-05-13
|
| 984 |
|
|
|2 20
|1 01
|x 0084
|a 84$029275052
|
